Understanding the Gap: Difficult-to-Treat vs. Severe Asthma

Severe asthma is actually a subset of difficult-to-treat asthma, not a separate condition. Of all asthma patients, 17% fall under the difficult-to-treat umbrella, but only 3.7% truly have severe asthma.

Difficult-to-Treat Asthma – The Modifiable Layer

This is the broader, outer category. The defining characteristic is asthma that remains uncontrolled despite medium- or high-dose inhaled corticosteroids (ICS) plus a second controller (LABA). Crucially, many of these cases have fixable underlying causes:

Inhaler technique — Up to 80% of patients use their inhaler incorrectly, making this one of the most overlooked drivers of poor control.
Adherence & Environment — Skipping medications, ongoing tobacco smoke exposure, or allergen contact frequently masquerade as treatment-resistant asthma.
Comorbidities — Conditions like obesity, GERD, chronic rhinosinusitis, and sleep apnea can mimic or amplify asthma symptoms. When these are addressed, clinical response often improves significantly.

Severe Asthma — The Refractory Core

Severe asthma is reserved for patients whose asthma persists even after all modifiable factors have been genuinely optimized. Key features include:

Truly refractory — Resistant to high-dose inhaled therapies and corticosteroids even with good adherence.
Retrospective diagnosis — It cannot be confirmed until therapy has been optimized and monitored for several months. This is critical; it prevents premature labeling.
FeNO Suppression Test — Specialists use this tool to distinguish poor adherence from true Type 2 refractory inflammation, helping determine who genuinely belongs in this category.

Key Clinical Insight

The most important takeaway is the diagnostic gap — the large space between 17% and 3.7%. Many patients are labeled as having severe asthma when they actually have difficult-to-treat asthma with correctable causes. This distinction matters enormously because severe asthma typically qualifies for expensive biologic therapies, while difficult-to-treat asthma should first go through a systematic process of eliminating modifiable factors. Jumping to a severe asthma diagnosis without this process leads to both under-treatment of the root cause and over-medicalization of the patient.

A Guide to Biologic Therapies For Severe Asthma

Understanding the Disease Landscape

Severe asthma is defined as uncontrolled disease despite high-dose inhaled corticosteroids (ICS) plus a second controller agent, or when it requires oral corticosteroids (OCS) to maintain control. The critical first step before initiating any biologic is phenotyping — distinguishing T2-high from T2-low inflammation, as this fundamentally shapes which therapy is appropriate.

T2-High inflammation is characterized by elevated eosinophils (≥150–300 cells/µL or ≥2–3% in sputum), raised FeNO (≥25 ppb), and elevated total serum IgE. This phenotype responds well to currently available biologics. T2-Low inflammation, by contrast, lacks these biomarkers and represents a significant unmet need, as existing therapies offer little benefit in this population.

The Role of Biologics: A Targeted Revolution

Biologics represent a paradigm shift in severe asthma management. Unlike broad immunosuppressants, they precision-target specific inflammatory mediators, reducing exacerbations, OCS dependence, and hospitalizations while improving lung function and quality of life. Each agent has a distinct mechanistic niche:

Anti-IgE — Omalizumab

Targets the allergic arm of T2 inflammation by neutralizing free IgE. It is the most established biologic, approved from age ≥6, and requires a positive perennial allergen test with IgE levels between 30–1500 IU/mL. It is especially suited to patients with allergic asthma and comorbid allergic rhinitis or food allergy.

Anti-IL-5 Pathway — Mepolizumab, Benralizumab, Reslizumab

These three agents target the eosinophilic axis, which is the dominant driver of T2-high inflammation in many patients.

Mepolizumab binds IL-5 itself (the key eosinophil survival cytokine), requiring eosinophils ≥150/µL, approved from age ≥6.
Benralizumab targets the IL-5 receptor, leading to near-complete eosinophil depletion via ADCC (antibody-dependent cytotoxicity). It requires eosinophils ≥300/µL and is approved from age ≥12.
Reslizumab also binds IL-5 but is administered intravenously and requires the highest eosinophil threshold (≥400/µL), approved only for adults ≥18. Its IV route can be a limitation in practice.

Dual IL-4/IL-13 Blockade — Dupilumab

Dupilumab blocks the shared IL-4Rα receptor, inhibiting both IL-4 and IL-13 signaling — two cytokines central to type 2 airway inflammation, mucus hypersecretion, and IgE class switching. Its biomarker threshold is eosinophils ≥150/µL and/or FeNO ≥25 ppb, giving it broader applicability. Approved from age ≥6, it also has the widest indication portfolio, including atopic dermatitis, chronic rhinosinusitis, and eosinophilic esophagitis — making it particularly attractive for patients with multiple type-2 comorbidities.

Anti-TSLP — Tezepelumab

Tezepelumab is arguably the most significant advance in recent years. By blocking TSLP (Thymic Stromal Lymphopoietin) — an epithelial-derived alarmin sitting upstream of the entire T2 cascade — it interrupts multiple inflammatory pathways simultaneously. Crucially, it has no biomarker threshold requirement, making it the only approved biologic suitable for both T2-high and potentially T2-low patients. Approved from age ≥12.

Clinical Pearls That Matter in Practice

The infographic highlights four management principles that are often underappreciated:

Biologics are add-on therapy, not replacements. ICS must never be stopped; low-dose ICS should continue alongside the biologic. This is a common misconception patients have.
Effectiveness assessment takes time. The recommended evaluation window is 4–6 months, looking for reduced OCS use, fewer exacerbations, and improved symptoms and lung function. Premature discontinuation is a clinical mistake.
Discontinuation carries real risk. Stopping a biologic is not straightforward — there is a meaningful risk of symptom rebound and exacerbation, so the decision requires careful shared decision-making.
Home administration improves adherence. Most SC biologics can be self-administered, but the first three doses should be given in a supervised clinical setting to monitor for hypersensitivity reactions.

The Future Pipeline: Where Is the Field Heading?

The pipeline signals several exciting directions:

Extended dosing intervals — Depemokimab (anti-IL-5) dosed every 6 months subcutaneously (currently in Phase III) could dramatically improve adherence and reduce treatment burden compared to monthly regimens.
Novel upstream targets — IL-33 inhibitors (Itepekimab) and ST2 inhibitors (Astegolimab) target another epithelial alarmin pathway, with particular promise in patients with low eosinophil counts who don’t qualify for current eosinophil-directed therapies.
Innovative delivery — Inhaled anti-TSLP (Ecleralimab) and ultra-long-acting TSLP blockade (Verekitug, up to 6 months) aim to deliver targeted therapy directly to the airway while extending dosing intervals.
Dual-target biologics — Lunsekimig, a nanobody blocking both IL-13 and TSLP simultaneously, in Phase II, could offer synergistic pathway inhibition in a single molecule — an elegant approach to the complexity of T2 inflammation.

Summary

Biologics have transformed severe asthma from a condition managed reactively with OCS — with all their systemic toxicity — to one managed proactively through precision immunology. The key to success lies in accurate phenotyping, matching the right biologic to the right biomarker profile, setting realistic expectations around timelines, and never abandoning foundational ICS therapy. As the pipeline matures, the field is moving toward longer-acting, broader-spectrum, and potentially T2-low-effective therapies that will extend these benefits to patients currently left without targeted options.